Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma

Figure 6

Axitinib inhibits tumor growth in vivo. Serially passaged (P5) MLS 1765 xenografts were transplanted into new NOD-SCID mice. When tumors reached approximately 200 mm³, mice were injected with 30 mg/kg axitinib or vehicle control (six mice per group) every second day for 12 days (day 7 to 18 after inoculation), as indicated by arrows and tumor size measured by digital calipers. Differences in tumor size were assessed by paired, two-tailed -test. The data are presented as the mean ± SEM. The dashed line represents the average tumor size when treatment commenced (a). On day 20, mice were culled, and tumors were excised, weighed (b), and photographed (c). Differences in tumor weight were assessed by paired, two-tailed -test. In (b), all individual data are presented, and horizontal lines indicate the mean ± SEM. In (c), all tumors are shown; note that one tumor did not grow.

(a)

(b)

(c)